Back

Elamipretide, to block mitochondrial dysfunction?

27 May 2019 (17:15 - 17:37)
Organised by:
Congress Presentation Part of: Upcoming and novel drugs in heart failure Drugs, Drug Targets HFA Premium Access Heart Failure 2019

About the speaker

Photo
Professor Christoph Maack

University Clinic Wuerzburg, Wuerzburg (Germany)

3 More presentations in this session

Presentation thumbnail
Targeting cardiac amyloidosis.
Professor S. Heymans (Maastricht, NL)
Slides Video
Presentation thumbnail
Targeting fibrosis: pirfenidone and beyond.
Professor R. De Boer (Rotterdam, NL)
Presentation thumbnail
Gene therapy.
Professor Y. Pinto (Amsterdam, NL)

Access the full session

Session thumbnail
Upcoming and novel drugs in heart failure

The Event

Event poster

Heart Failure 2019

27 May 2019 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Mitochondrial targeting by Elamipretide improves cardiac mitochondrial function without improving cardiovascular performance in HFpEF
23 April 2026
thumbnail
Congress Presentation
Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy
29 June 2021
thumbnail
Congress Presentation
Impact of oxygen deficiency on changes in respiratory chain proteins and membrane potential of cardiac mitochondria
29 June 2021
thumbnail
Congress Presentation
Effect of SGLT2i empagliflozin on left ventricular and mitochondrial function in a porcine model of anthracycline-induced cardiotoxicity
20 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources